17-43091931-C-G

Variant summary

Our verdict is Benign. Variant got -16 ACMG points: 0P and 16B. BP4_StrongBP6_Very_StrongBS2

The NM_007294.4(BRCA1):​c.3600G>C​(p.Gln1200His) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000215 in 1,614,128 control chromosomes in the GnomAD database, including 3 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★). Another nucleotide change resulting in the same amino acid substitution has been previously reported as Likely benign in Lovd.

Frequency

Genomes: 𝑓 0.0012 ( 2 hom., cov: 32)
Exomes 𝑓: 0.00012 ( 1 hom. )

Consequence

BRCA1
NM_007294.4 missense

Scores

1
7
11

Clinical Significance

Benign/Likely benign criteria provided, multiple submitters, no conflicts B:16O:1

Conservation

PhyloP100: 0.672
Variant links:
Genes affected
BRCA1 (HGNC:1100): (BRCA1 DNA repair associated) This gene encodes a 190 kD nuclear phosphoprotein that plays a role in maintaining genomic stability, and it also acts as a tumor suppressor. The BRCA1 gene contains 22 exons spanning about 110 kb of DNA. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC). This gene product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants, some of which are disease-associated mutations, have been described for this gene, but the full-length natures of only some of these variants has been described. A related pseudogene, which is also located on chromosome 17, has been identified. [provided by RefSeq, May 2020]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Benign. Variant got -16 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.02793637).
BP6
Variant 17-43091931-C-G is Benign according to our data. Variant chr17-43091931-C-G is described in ClinVar as [Likely_benign]. Clinvar id is 54930.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr17-43091931-C-G is described in Lovd as [Likely_benign]. Variant chr17-43091931-C-G is described in Lovd as [Benign].
BS2
High Homozygotes in GnomAd4 at 2 AD,AR gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
BRCA1NM_007294.4 linkc.3600G>C p.Gln1200His missense_variant Exon 10 of 23 ENST00000357654.9 NP_009225.1 P38398-1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
BRCA1ENST00000357654.9 linkc.3600G>C p.Gln1200His missense_variant Exon 10 of 23 1 NM_007294.4 ENSP00000350283.3 P38398-1

Frequencies

GnomAD3 genomes
AF:
0.00112
AC:
170
AN:
152214
Hom.:
1
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.00410
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.000231
AC:
58
AN:
250966
Hom.:
0
AF XY:
0.000177
AC XY:
24
AN XY:
135682
show subpopulations
Gnomad AFR exome
AF:
0.00339
Gnomad AMR exome
AF:
0.0000869
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.000117
AC:
171
AN:
1461796
Hom.:
1
Cov.:
33
AF XY:
0.000114
AC XY:
83
AN XY:
727180
show subpopulations
Gnomad4 AFR exome
AF:
0.00451
Gnomad4 AMR exome
AF:
0.0000895
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.0000116
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.00000540
Gnomad4 OTH exome
AF:
0.000149
GnomAD4 genome
AF:
0.00116
AC:
176
AN:
152332
Hom.:
2
Cov.:
32
AF XY:
0.00128
AC XY:
95
AN XY:
74484
show subpopulations
Gnomad4 AFR
AF:
0.00423
Gnomad4 AMR
AF:
0.00
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.00
Gnomad4 OTH
AF:
0.00
Bravo
AF:
0.00119
ESP6500AA
AF:
0.00272
AC:
12
ESP6500EA
AF:
0.00
AC:
0
ExAC
AF:
0.000313
AC:
38
Asia WGS
AF:
0.000289
AC:
1
AN:
3478

ClinVar

Significance: Benign/Likely benign
Submissions summary: Benign:16Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not specified Benign:3Other:1
Sep 19, 2013
ITMI
Significance: not provided
Review Status: no classification provided
Collection Method: reference population

- -

May 02, 2017
Genetic Services Laboratory, University of Chicago
Significance: Likely benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Feb 05, 2014
GeneDx
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -

Apr 25, 2017
PreventionGenetics, part of Exact Sciences
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Breast-ovarian cancer, familial, susceptibility to, 1 Benign:3
Nov 03, 2014
Michigan Medical Genetics Laboratories, University of Michigan
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

May 29, 2002
Breast Cancer Information Core (BIC) (BRCA1)
Significance: Benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

Sep 03, 2014
Counsyl
Significance: Likely benign
Review Status: criteria provided, single submitter
Collection Method: literature only

- -

Hereditary cancer-predisposing syndrome Benign:3
Nov 17, 2015
Color Diagnostics, LLC DBA Color Health
Significance: Likely benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Nov 18, 2014
Ambry Genetics
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -

Jan 28, 2021
Sema4, Sema4
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: curation

- -

Hereditary breast ovarian cancer syndrome Benign:3
Feb 02, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Feb 14, 2017
Institute for Biomarker Research, Medical Diagnostic Laboratories, L.L.C.
Significance: Likely benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Nov 16, 2021
National Health Laboratory Service, Universitas Academic Hospital and University of the Free State
Significance: Likely benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Breast and/or ovarian cancer Benign:1
Nov 04, 2013
Foulkes Cancer Genetics LDI, Lady Davis Institute for Medical Research
Significance: Benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

- -

BRCA1-related cancer predisposition Benign:1
Sep 23, 2024
All of Us Research Program, National Institutes of Health
Significance: Likely benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

not provided Benign:1
Dec 09, 2020
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Malignant tumor of breast Benign:1
-
Department of Pathology and Laboratory Medicine, Sinai Health System
Significance: Benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

The BRCA1 p.Gln1200His variant was identified in at least 11 of 122840 proband chromosomes (frequency 0.005) from individuals or families with breast cancer, ovarian cancer or prostate cancer, and was identified in 1 of 2892 control chromosomes (frequency: 0.0003) (Anczukow 2008, Capanu 2011, Caux-Moncoutier 2011, Judkins 2005, Lee 2008, McKean-Cowdin 2005, Newman 1998, Osorio 2007, Zuhlke 2004). The variant was also identified in the HGMD, UMD (7X as a neutral variant), and the BIC database (17X with no clinical importance). The variant was listed in UMD with a co-occurring pathogenic mutation in BRCA1 (c.5041insATTA (p.Thr1681IlefsX3)), and Judkins (2005) also identified the variant in trans with a pathogenic BRCA1 mutation (BRCA1 4730insG), increasing the likelihood that this variant does not have clinical importance. The variant was listed in dbSNP (ID: rs56214134) with a minor allele frequency of 0.001 (1000 Genomes Project), and in the NHLBI Exome Sequencing Project with a frequency of 0.003 in African American alleles, increasing the likelihood that this may be a low frequency benign variant in certain populations of origin. This residue is not conserved in mammals and lower organisms and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM) do not suggest a high likelihood of impact to the protein. However, this information is not predictive enough to rule out pathogenicity. A functional study by Anczukow (2008) did not detect an effect of the variant on intron 11 splicing efficiency. In addition, two in silico studies using multifactorial likelihood ratio models suggest that this is likely a neutral variant (Lindor 2012, Osorio 2007). In summary, based on the above information, this variant meets our laboratory's criteria to be classified as benign. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.16
BayesDel_addAF
Benign
-0.20
T
BayesDel_noAF
Uncertain
-0.060
CADD
Benign
12
DANN
Benign
0.97
DEOGEN2
Uncertain
0.50
T;.;.;.
Eigen
Benign
-0.63
Eigen_PC
Benign
-0.80
FATHMM_MKL
Benign
0.27
N
LIST_S2
Benign
0.79
T;T;T;T
M_CAP
Pathogenic
0.46
D
MetaRNN
Benign
0.028
T;T;T;T
MetaSVM
Benign
-0.45
T
MutationAssessor
Uncertain
2.5
M;M;.;.
PrimateAI
Benign
0.22
T
PROVEAN
Uncertain
-3.6
D;D;D;D
REVEL
Uncertain
0.46
Sift
Uncertain
0.018
D;D;D;D
Sift4G
Uncertain
0.041
D;D;T;D
Polyphen
0.21
B;.;.;P
Vest4
0.49
MutPred
0.30
Loss of MoRF binding (P = 0.0854);Loss of MoRF binding (P = 0.0854);.;Loss of MoRF binding (P = 0.0854);
MVP
0.50
MPC
0.23
ClinPred
0.050
T
GERP RS
1.2
Varity_R
0.093
gMVP
0.19

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs56214134; hg19: chr17-41243948; API